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 Abstract 
 
 
Endothelial derived nitric oxide (NO) is essential in the regulation of blood 
pressure and attenuates leukocyte-endothelial interactions associated with vascular injury. 
However, when endothelial-derived NO is decreased, endothelial dysfunction results and 
promotes inflammation characterized by increased leukocyte-endothelial interactions. 
Under normal conditions, eNOS produces NO in the presence of an essential cofactor, 
tetrahydrobiopetrin (BH4) by facilitating the reduction of molecular oxygen to L-arginine 
oxidation and generation of L-citrulline.  Whereas uncoupled eNOS refers to the electron 
transfer that becomes uncoupled to L-arginine oxidation and therefore superoxide (SO) is 
generated when the dihydrobiopetrin (BH2) to BH4 ratio is increased. SO is subsequently 
converted to hydrogen peroxide as a result. However, the role of uncoupled eNOS 
promoting endothelial dysfunction and leukocyte-endothelial interactions in not well 
characterized in vivo.  
This study examined the role of eNOS uncoupling by superfusing BH2 (100 or 
200 µM) by itself and BH2 (100 µM) combined with BH4 (100 or 250 µM) in rat 
mesenteric venules on leukocyte rolling, adherence, and transmigration by using 
intravital microscopy. The effects of BH2 were compared to Krebs’ buffer, to NOS 
inhibitor, N
G
-nitro-L-arginine methyl ester (L-NAME, 50 µM), and to the combination of 
BH2/BH4. We found that superfusion of BH2 (100 µM n=6, 200 µM n=6, both P<0.05) 
significantly increased leukocyte rolling, adherence, and transmigration, similar to L-
NAME (n=6, P<0.01), within a 2 hr period compared to Krebs’ buffer (n=6) control rats 
on these three parameters. The BH2 induced response was significantly attenuated by 
BH4 (100 µM n=6, 250 µM n=6, both P<0.05) dose dependently.  
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These results were further confirmed by hematoxylin/eosin staining which 
showed significantly decreased leukocyte adherence and transmigration in BH4 treated 
rats compared to BH2 (100 µM n=6, 200 µM n=6, both P<0.05) controls or L-NAME 
(n=6, P<0.01). The data suggest that eNOS uncoupling may be an important mechanism 
mediating inflammation-induced vascular injury. 
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Introduction 
Endothelial Function 
 Endothelial function plays a vital role in the normal physiological process. 
Endothelium contains a monolayer of endothelial cells that acts as a barrier and is present 
between the blood vessel wall and the circulating blood. This tissue functions as a barrier 
by transferring molecules through this semi-permeable layer as well as maintaining 
vascular homeostasis [1, 2, 3]. In addition to serving as a barrier, these cells recruit and 
modulate leukocytes which may result in cell activation. Normal endothelium has an anti-
thrombotic surface that prohibits circulating leukocytes from adhering to the vasculature. 
This allows ample blood flow by normalizing vasomotor tone, thrombosis, and immune 
and inflammatory responses by regulating leukocyte interactions in the vessel wall [2]. 
Endothelial cells produce nitric oxide (NO) which serves to mediate the anti-
inflammatory and anti-thrombotic properties and prevent damage to normal vascular 
endothelium. Impaired NO production and release contributes to endothelial dysfunction 
that can lead to inflammation-mediated vascular injury. This makes it an ideal target in 
new therapies for diseases such as atherosclerosis, hyperglycemia, shock, diabetes, and 
ischemia-reperfusion (I/R) injury [2, 4]. 
  
Nitric Oxide/Endothelial Nitric Oxide Synthase (eNOS)  
 Nitric oxide is present in all blood vessels and is involved in regular vascular 
function. It is a key cellular signaling molecule that has a vital role in many biological 
processes. Because NO is a major mediator of endothelium-dependent vasodilation, it 
acts as an important determinant of cardiovascular health [1].  NO is made in endothelial 
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cells from L-arginine through the action of the membrane bound enzyme endothelial NO 
synthase (eNOS).  Calcium is released from the sarcolemma storage site from activating 
stretch and/or Gq coupled receptors which results in an increase in intracellular calcium. 
Thereafter, calcium associates with calmodulin to activate the enzyme eNOS which 
produces NO from its precursor L-arginine forming L-citrulline as a byproduct.  
Tetrahydrobiopterin (BH4) and nicotinamide-adenine-dinucleotide phosphate 
(NADPH) are both essential cofactors in this electron chain reaction [5, 6, 7, 8]. NADPH 
begins the electron transport chain which binds flavin adenine dinucleotide and flavin 
mononucleotide to the prosthetic heme group.  This is then activated by BH4 in the 
presence of molecular oxygen to produce NO and this is referred to as eNOS coupling. 
Whereas when the dihydrobiopterin (BH2), the oxidized form of BH4, to BH4 ratio 
increases, the product profile of eNOS switches from NO to superoxide (SO). BH2 
competes with BH4 binding at the oxygenase domain of eNOS with equal affinity [9]. In 
the presence of BH2, the electron transfer becomes uncoupled to L-arginine and eNOS 
utilizes molecular oxygen instead to produce SO [8]. This is referred to as eNOS 
uncoupling as seen in Figure 1.  
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Figure 1: Illustration of the coupled eNOS and uncoupled eNOS [Adapted from 8]. 
 
 
In the normal physiological process, after NO is produced as a byproduct from L-
arginine, NO diffuses into vascular smooth muscle cells adjacent to the endothelium 
where it binds to and activates the enzyme guanylyl cyclase which catalyzes the 
dephosphorylation of guanosine triphosphate to cyclic guanosine monophosphate, an 
important second messenger that induces smooth muscle relaxation as seen in Figure 2 
[3, 10]. 
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Figure 2: Illustration of the mechanism of action of nitric oxide displaying how it 
maintains endothelium normal function. 
 
 
When NO forms, it has a very short half life (seconds) and can react with SO to 
form peroxynitrite, which in turn can generate damage to the cell membrane causing lipid 
peroxidation. SO can quench NO thus reducing NO bioavailability and induce endothelial 
dysfunction.  N
G
-nitro-L-arginine methyl ester (L-NAME) inhibits NO synthesis by 
competing with L-arginine. L-NAME is used to cause endothelial dysfunction and 
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consequently induce leukocyte-endothelial interactions which can simulate early 
reperfusion events [4, 11].  
 Furthermore, NO regulates vascular tone, controls mitochondrial oxygen 
consumption, and inhibits leukocyte adhesion, aggregation, and activation [12, 13]. When 
normal NO production is impaired, cardiovascular diseases such a hypertension, 
atherosclerosis, angiogenesis-associated disorders, diabetes, and hypercholesterolaemia 
may occur [6, 12].  
  
Endothelial Dysfunction 
 Endothelial dysfunction is an early and frequent characteristic of cardiovascular 
disease conditions that refers to the decreased bioavailability of NO and prostacyclin 
[14]. This term is used to describe an impairment of endothelium-dependent 
vasorelaxation caused by a reduction in NO activity in the vasculature or increased SO 
release from leukocytes and vascular endothelium. This decrease in NO bioavailability 
may also transpire if eNOS is not fully expressed or activated due to the lack of L-
arginine or the increased BH2 to BH4 ratio. Additionally, reactive oxygen species (ROS) 
may increase NO degradation [15].  Endothelial dysfunction often is associated with 
shock, atherosclerosis, I/R, hypertension, diabetes, and other vascular pathophysiological 
conditions [11, 15].  
 
Oxidative Stress/Reactive Oxygen Species (ROS) 
Oxidative stress causes cellular damage due to the unrestrained action of ROS 
molecules [16]. These molecules are derived from oxygen and its’ derivatives which 
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include the following free radicals: the SO anion, the hydroxyl radical, and large 
quantities of NO (i.e. micromolar amounts) derived from inducible NO synthase. 
Additionally, hydrogen peroxide (H2O2), peroxynitrite, and hypochlorous acid possess 
analogous oxidizing capabilities [1, 15, 16, 17].  ROS generation occurs under normal 
physiological conditions as well as pathophysiological conditions. ROS production in 
conjunction with endothelial activation and inflammatory cell recruitment creates an 
equilibrium between the oxidizing agent formation and the protective antioxidant 
mechanism removal. The balance between oxidant and antioxidant functions controls 
how much ROS is produced by endothelial cells, and the imbalance between these 
processes will inhibit normal endothelial function [1, 17]. It is termed oxidative stress 
when this balance shifts in favor of ROS production [17]. This action is stimulated in the 
presence of cardiovascular risk factors such as hypertension, diabetes, 
hypercholesterolemia, stroke, chronic smoking, and peripheral vascular diseases [16, 18].  
In the cardiovascular system, three main sources of ROS production that inactive 
NO performance have been studied. These include xanthine oxidase, hydrogenated 
nicotinamide adenine dinucleotide (NADH)/nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, and eNOS [1, 16, 17, 18]. Xanthine oxidoreductase is a molybdenum-
conjugated enzyme that exists in two interconvertible forms: xanthine dehydrogenase or 
xanthine oxidase – both of which catalyze xanthine to hypoxanthine and urate during purine 
metabolism. Xanthine dehydrogenase reduces NAD+, while xanthine oxidase prefers 
molecular oxygen leading to production of the SO anion and subsequently, H2O2 via 
superoxide dismutase (SOD) [15, 16].  
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NADH/NADPH oxidase is the enzyme that predominately drives SO radical 
production especially in leukocytes [15, 16]. It is also known to reside in vascular cells 
(particularly endothelial cells) and smooth muscle cells [16].  NADH/NADPH oxidase is 
regulated by cytokines and hormones that activate coupled Gq receptors and have been 
identified throughout the pathogenic process involved in vascular conditions. Most 
importantly, current data suggests that activation of SO from NADH/NADPH oxidase 
can initiate endothelial dysfunction by decreasing the bioavailability of NO [15].   
The enzyme eNOS has been known to be a third source of ROS production in 
vascular tissues [7]. The mechanism behind this enzyme requires the cofactor BH4 bound 
near the heme group to transfer electrons to L-arginine in order to produce NO as seen in 
Figure 1 [15, 16]. In the presence of BH2, eNOS uncouples and as a result produces SO 
which causes a subsequent increase in H2O2. The reduction in NO levels in addition to 
the increase in SO levels further intensifies any oxidative stress present [16]. Recent 
preliminary studies have also shown cytochrome p450 to be an important source of SO 
and contribute to the inactivation of NO [1, 15]. Moreover, incomplete oxidative 
phosphorylation from mitochondria may contribute to additional oxidation of BH4 to BH2 
intracellularly. Consequently, evidence suggests that endothelial dysfunction may be 
caused by the accelerated inactivation of NO by ROS via the previously mentioned major 
enzyme systems and this has been further implicated by numerous pathophysiological 
conditions [15, 16, 18].  
 
 
 
                                                                              
                                                                          
8 
 
Leukocyte-Endothelial Interactions 
Leukocyte-endothelial cell adhesion is primarily generated by shear stress and 
decreased endothelial-derived NO which is caused by blood flow in postcapillary 
venules. The stress on the walls of the venules establishes the amount of leukocyte rolling 
and adhesion, while increases in the movement of blood are likely to counteract 
leukocyte-endothelial cell adhesion [19]. Leukocytes adhere to the side of the 
postcapillary venules and pass across the border in a process called diapedesis, or 
transmigration as seen in Figure 3 [9, 11]. Postcapillary venules are the preferred site of 
migration of blood not only because they begin the venous system, but also because they 
lack a significant muscle cell layer, possess a larger lumen than capillaries, and highly 
express cellular adhesion molecules (CAMs) [17]. CAMs defend the host cell by 
supplying the basis for cell communication, trafficking, and immune surveillance [17, 
20].  
 
 
Figure 3:  The leukocyte-endothelial interaction cascade [21]. 
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CAMs are known to facilitate blood-endothelial cell interactions that can take 
place in all areas of the microvasculature under specific physiological and 
pathophysiological conditions. Disease may occur due to the loss of endothelial NO since 
the dysfunctional endothelium expresses a proinflammatory phenotype exemplified by 
atherogenic CAMs [22]. Selectins, integrins, and supergene immunoglobins make up the 
different families of adhesions molecules involved in the three stages of leukocyte 
recruitment (i.e. rolling, adherence, and transmigration) [23].  
 P-selectin is a CAM expressed on the surface of activated endothelial cells and 
platelets. When inactive, P-selectin in found in the cytoplasm of endothelial cells referred 
to as Weibel-Palade bodies and in alpha granules in platelets [23, 24]. It is activated and 
mobilized to the cell membrane within minutes of cytokine recognition via thrombogenic 
and inflammatory mediators. Decreased endothelial-derived NO bioavailability induces 
the upregulation of P-selectin. Because P-selectin expression is short-lived (i.e. minutes), 
it makes an ideal candidate to induce leukocyte-endothelial interactions [24]. During 
inflammation, endothelial P-selectin recruits leukocytes into postcapillary venules, 
whereas platelet-associated P-selectin promotes the aggregration of leuckocytes with 
platelets to form thrombi [23]. Generally, P-selectin has been noted to be the primary 
CAM affiliated with leukocyte rolling along the venular wall [24, 25].  
Five members of the immunoglobin superfamily act as adhesion molecules during 
leukocyte-endothelial interactions [23]. Intracellular adhesion molecule-1 (ICAM-1) and 
platelet endothelial cell adhesion molecule-1 (PECAM-1) are the most extensively 
studied [20]. ICAM-1 is constitutively expressed on the surface of vascular endothelial 
cells at low levels. Expression can be increased by stimulation from interleukins, tumor 
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necrosis factor alpha, interferon gamma, lipopolysaccharide, and decreased endothelial-
derived NO bioavailability and increased SO/H2O2 release [20, 26, 27]. It is an essential 
signaling molecule connecting leukocyte adhesive interactions with downstream 
endothelial cell actions [28].  ICAM-1 serves to arrest leukocyte rolling and mediates 
firm adhesion between leukocytes and the vascular endothelium in postcapillary venules. 
The leukocyte integrin CD11a/18b binds to ICAM-1 to promote firm adhesion. This 
action precedes PECAM-1-dependent transmigration between endothelial cells [19].  
PECAM-1, another member of the immunoglobulin superfamily, is an adhesion 
molecule that is constitutively expressed on leukocytes, platelets, and endothelial cells. It 
is mostly found at the intracellular borders of adjoining cells and is involved in neutrophil 
recruitment to inflamed sites in the body [9, 23, 29]. PECAM-1 can mediate adhesion of 
leukocytes through hemophilic or heterophilic interactions [23]. Most importantly, it is 
required for leukocyte transmigration, or diapedesis, through the perivascular 
subendothelial basal lamina [9, 23]. After transmigration, leukocytes can release harmful 
molecules (i.e. SO) and enzymes (i.e. elastase) which cause cell and tissue injury. Figure 
4 depicts the steps and CAMs involved in leukocyte-endothelial cell recruitment.  
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Figure 4:  Steps and CAMs involved in leukocyte-endothelial cell recruitment 
[Adapted from 23]. 
 
 
Endothelial Dysfunction in Pathological Conditions 
Diabetes 
 It is estimated that 25.8 million people in the United States suffer from diabetes, 
up from 23.7 million in 2007. The majority of diabetics suffer vascular complications 
associated with the disease which include blindness, kidney failure, hypertension, 
accelerated atherosclerosis, heart disease, and stroke [30, 31]. Change of diabetic 
microvasculature due to increased permeability to macromolecules and inflammation is 
known to cause diabetes complications. A number of studies have shown that increased 
endothelial permeability is an early sign of endothelial dysfunction displayed in diabetes 
and hyperglycemia found in both humans and animals [31, 32]. Both acute and chronic 
hyperglycemia increases leukocyte adhesion to the vascular walls of endothelium in 
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postcapillary venules and as a result decreases NO production [32]. Vascular alterations 
are the most frequent causes of morbidity and mortality in patients with diabetes which 
directly correlates with leukocyte adhesion in postcapillary venules associated with 
endothelial dysfunction [31, 33].  
 
Ischemia-Reperfusion (I/R) Injury   
 Ischemia is a restriction of blood and oxygen to an organ which results in tissue 
damage or dysfunction and can eventually lead to cell necrosis [17]. Reperfusion refers to 
the restoration of blood flow to vessels and organs after a period of ischemia and can 
induce additional leukocyte-mediated injury. I/R produces an inflammatory response that 
both increases local injury and leads to systemic damage [7]. Although there are numerous 
improvements in interventional techniques, imaging, and drugs, morbidity from 
reperfusion remains remarkably high. The pathophysiological mechanisms involved as 
well as the development of potential therapeutic strategies need to be further studied in 
order to decrease the death rate [17]. A major event leading to endothelial dysfunction is 
the loss of endothelial cell release of NO which happens a few minutes after blood flow 
has been reestablished to an ischemic organ. This dysfunction is followed by neutrophil 
amplication which leads to capillary plugging and edema formation which in turn reduces 
coronary blood flow [19]. I/R is responsible for the complex interplay between local and 
systemic inflammation present in endothelial dysfunction that leads to numerous 
cardiovascular conditions.  
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Atherosclerosis 
 Vascular endothelium dysfunction which is associated with increased oxidative 
stress and decreased NO production is considered as an early and vital event in the 
pathogenesis of countless clinical cases involving atherosclerosis [11]. Atherosclerosis is 
a chronic disease that involves inflammatory mechanisms in which artery walls thicken 
due to a build-up of lipids [34]. The beginning stages are classified by endothelial cell 
injury characterized by recruitment of blood leukocytes which is associated with 
numerous predisposing risk factors for atherosclerosis including diabetes, smoking, 
hypertension, and hypercholesterolemia [1, 34].  Lipid accumulation then occurs in the 
arterial walls along with increased adherence of monocytes, macrophages, and T 
lymphocytes. Eventually, these cells transmigrate and release cytokines and growth 
factors that contribute to neointimal lesion formation [35]. Increasing evidence suggests 
that both inflammation and immune processes play a role in the acute thrombotic event of 
atherosclerosis [34].  
 
Hypertension 
 Hypertension is widely known to be a risk factor of coronary disease and is found 
in over 20% of Western adult populations. It is defined as a systolic and/or diastolic 
pressure greater than or equal to 140 and/or 90 mmHg, or if the patient is being treated 
with anti-hypertensive drugs [16, 36]. NO is produced by endothelial cells to maintain 
vascular tone and normal function. Increased oxidative stress in hypertensive states has 
been known to lead to a reduced bioavailability of NO [1]. This decrease in NO 
bioavailability and therefore shift towards ROS has been shown to act as the central 
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method through which endothelial dysfunction occurs in hypertensive patients. In 
spontaneously hypertensive rats, the administration of pharamacological BH4 
supplementation exhibits ameliorated endothelial dysfunction [8]. Regardless of whether 
the origin is essential or secondary to endocrine or renal processes, endothelial 
dysfunction is now certainly recognized to be imperative in the pathophysiology of 
hypertension [16, 37]. 
 
Tetrahydrobiopterin (BH4)/Dihydrobiopterin (BH2) 
When BH4 is present, eNOS generates NO by converting L-arginine into L-
citrulline. However, when BH4 is oxidized to BH2 under conditions of oxidative stress, 
such as I/R, the ratio of BH2 to BH4 can be increased. Under these conditions, BH2 
competes with BH4 for binding at the oxgenase domain of eNOS with equal affinity 
causing eNOS to use molecular oxygen as a substrate instead of L-arginine to produce SO 
[6, 8, 37]. Oxidative stress and reduced NO bioavailability, brought on by SO production 
from the addition of BH2, comprises a distinctive characteristic and common generic 
marker for endothelial dysfunction in chronic vascular diseases, such as atherosclerosis 
and hypertension [9, 37]. Moreover, reduced serum BH4 levels are associated with 
coronary artery disease, hypertension, and atherosclerosis [36]. The reduction of NO 
bioavailability under these conditions can often foreshadow undesirable cardiovascular 
outcomes, such as increased leukocyte-endothelial interactions, which can lead to 
microvascular plugging and an overall reduction in perfusion to tissue [7, 11, 19]. 
The availability of BH4 to function as an essential cofactor in order to facilitate 
eNOS to produce NO is well described regarding in vitro systems [6]. BH4 functions to 
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aid in the coupling of electron transfer at the heme domain of eNOS to cause chemical 
reduction of molecular oxygen and L-arginine oxidation to generate NO.  Under normal 
physiological conditions BH4 is required for eNOS to produce NO which is important to 
maintain normal blood flow and diastolic blood pressure [38]. However, incomplete 
oxidative phosphorylation in dysfunctional mitochondrial endothelium may lead to the 
initial oxidation of BH4 resulting in increased BH2 to BH4 ratio leading to eNOS 
principally producing SO instead of NO [6, 22]. Uncoupled eNOS can then generate 
additional SO to increase oxidation of BH4 and BH2/BH4 ratio [7].  
Previous studies have revealed that BH4 dose-dependently increases NO release in 
non-ischemic rat aortic segments as well as in femoral I/R in vivo. Whereas, BH2 dose-
dependently decreases NO release in these preparations [7, 11, 39]. Furthermore, BH2 
resulted in cardiac contractile dysfunction associated with increased leukocyte adherence 
and transmigration in myocardial I/R compared to BH4 treatment. By contrast, BH4 
significantly reduced leukocyte adherence/transmigration and increased postreperfused 
left ventricular developed pressure in isolated rat hearts compared to control and BH2 
treated hearts [7, 11, 39]. These results collectively suggest that BH2 may induce 
leukocyte rolling, adherence and transmigration in rat mesenteric venules via uncoupled 
eNOS by reducing NO production which is similar to previous studies utilizing L-
NAME, a NOS inhibitor, to induce leukocyte-endothelial interactions by intravital 
microscopy. Nevertheless, the role of eNOS uncoupling in regulating leukocyte-
endothelial interactions has not been confirmed in vivo in real-time.   
Therefore, BH2 and BH4 serve as pharmacological tools to stimulate and attenuate 
leukocyte-endothelial interactions using intravital microscopy to monitor these responses 
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in mesenteric venules of  anesthetized rats.  Adhesion molecule, such as P-selectin and 
ICAM-1, expression will be further determined in this setting. This project will establish 
the basis for the future study of combining an eNOS activity enhancer or inhibitor with 
BH2 to facilitate or attenuate leukocyte-endothelial interactions in the presence/absence 
of BH4. The long-term goal of this project will provide experimental evidence to support 
novel pharmacological intervention in the settings of vascular endotheial dysfunction 
associated with ischemic heart disease, coronary bypass/angioplasty, and organ 
transplantation.   
 
Hypothesis 
The present study uses intravital microscopy to observe, in real time, leukocyte-
endothelial interactions at the cellular level within rat mesenteric post capillary venules 
[4, 7, 11]. BH2 was administered in order to reduce the cellular BH4/BH2 ratio and 
facilitate eNOS uncoupling to decrease NO bioavailability and increase leukocyte- 
endothelial interactions. Moreover, the effects of BH2 to enhance leukocyte-endothelial 
interactions will be compared to tradition tools such as L-NAME to delineate the 
importance of eNOS uncoupling compared to inhibiting eNOS activity with a methyl 
ester analog of L-arginine. It was hypothesized that administration of BH4 to increase the 
BH4/BH2 ratio will attenuate the leukocyte-endothelial interactions induced by BH2.  The 
proposed project serves as a basis for future study of drugs that relate to 
pathophysiological conditions, such as I/R, stroke, and cardiovascular diseases [37]. 
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Methods 
Intravital Microscopy 
 Vascular endothelium plays an essential role in maintaining the homeostatic 
properties of the cardiovascular system in the human body [3]. Intravitral microscopy 
provides a means to explore the leukocyte-endothelial interactions occurring at a 
microscopic level. Although often associated with a mild inflammatory response, it is 
most advantageous to analyze vascular endothelium in vivo. This quantitative and 
qualitative technique provides direct observation of leukocyte-endothelial interactions in 
real time [11, 40]. It allows the supervision of microcirculation changes in live animals. 
Additionally, it clarifies results that were acquired through in vitro experiments.  
 
Experimental Setup 
 The Institutional Animal Care and Use Committee of the Philadelphia College of 
Osteopathic Medicine have approved all animals used in this study. Animals were 
allowed free access to food and water throughout the entire study and were housed in an 
animal facility that maintained 12 hour light-dark cycle conditions. Male Sprague-
Dawley rats, weighing 275 to 325g, were anesthetized with 60 mg/kg pentobarbital 
sodium intraperitoneally (i.p., induction anesthesia) and maintained via 30 mg/kg 
pentobarbital sodium (i.p.) as previously described [11].  A PE-50 polyethylene catheter 
was inserted in the left carotid artery for monitoring of mean arterial blood pressure 
(MABP). The abdominal cavity was opened via a midline laparotomy, and a loop of ileal 
mesentery was exteriorized and placed in a temperature controlled Plexiglas chamber for 
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observation of leukocyte-endothelial interactions via intravital microscopy as shown in 
figure 5 (Nikon Corp., Tokyo, Japan).  
Krebs’ buffer alone, Krebs’ buffer containing 100 or 200 µM concentrations of BH2 
(MW= 239.2; Cayman Chemicals) alone or in the presence of 100 or 250 µM BH4 
(MW=314.2; Cayman Chemicals), as well as L-NAME, was used to superfuse the rat 
mensentery for 2 hours. The Krebs’ buffer has the following composition (in mmol/l):17 
dextrose, 120 NaCl, 25 NaHCO3, 2.5 CaCl2, 0.5 EDTA, 5.9 KCl, and 1.2 MgCl2. The 
solution was aerated with 95% N2-5% CO2 and equilibrated at a pH of 7.3-7.4 at 37 
degrees celsius. The leukocyte-endothelial interactions were recorded for a 2 minute 
observation period during baseline and at 30 minute intervals after superfusion of Krebs’ 
buffer or drugs. The image was analyzed by Image-pro (Media Cybernetics, Inc., 
Bethesda, MD).   
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Figure 5:  Experimental setup for intravital microscopy. Inserted picture in upper 
right  Exteriorized loop of mesenteric tissue undergoing superfusion of 
test solution.  
 
 
 Analysis of leukocyte-endothelial interactions was based on the following 
criteria:1) Leukocytes will be considered to be rolling if they are moving at a velocity 
significantly slower than that of red blood cells and expressed as the number of rolling 
leukocytes per minute. 2) Leukocytes are judged to be adherent if they remain stationary 
for >30 seconds. Adherence is expressed as the number of leukocytes adhering to the 
endothelium/100 µm of vessel length. 3) The number of extravasated leukocytes in the 
rat mesenteric tissue is counted in the tissue area adjacent to the postcapillary venules and 
normalized with respect to perivascular area (20x100 µm) [4]. 
                                                                              
                                                                          
20 
 
Treatment Groups 
 The experimental design consists of seven groups (with six subjects in each 
group) for recording leukocyte-endothelial interactions by intravital microscopy and 
performing hematoxylin/eosin staining on the excised mesenteric tissue thereafter. The 
proposed concentration of the drugs are based on their dose-response effects from 
previous cardiac function, aortic segment and femoral I/R studies [7, 11, 22]. Part of the 
superfused mesenteric tissue during the intravital microscopy experiment was preserved 
in 4% paraformaldehyde solution in PBS to be later used for hematoxylin/eosin staining. 
The remaining tissue sample was quickly frozen with liquid nitrogen and stored it at -80 
degrees celsius. The stored mesenteric tissue from different experimental groups will be 
used to investigate the expression of P-selectin and ICAM-1 by western blot and/or 
immunohistochemistry in future studies [22].    
 
Treatment Groups:  
 
1. Control:          Superfusion of Krebs’ buffer alone to determine if the 
animal surgical preparation and the physiological buffer can cause an 
increase in leukocyte-endothelial interactions. 
2. L-NAME:          Superfusion of 50 µM to determine if this non-selective 
NOS inhibitor can cause an increase in leukocyte-endothelial interactions.  
3. BH2:          Superfusion of 100 µM to determine the dose-dependent 
response by increasing the BH2/BH4 ratio to induce leukocyte-endothelial 
interactions.  
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4.  BH2:          Superfusion of 200 µM to determine a dose-dependent 
response by further increasing the BH2/BH4 ratio that can induce 
leukocyte-endothelial interactions. 
5. BH4:          Superfusion of 250 µM to determine if BH4 alone exerts any 
effect on leukocyte-endothelial interactions compared to the Krebs’ buffer 
control. 
6. BH2 + BH4:          Superfusion of 100 µM BH2 + 100 µM BH4 to 
determine the dose-dependent anti-BH2 induced inflammation response if 
there is an increase in the BH2/BH4 ratio to 1:1. 
7. BH2 + BH4:          Superfusion of 100 µM BH2 + 250 µM BH4 to 
determine the dose-dependent anti-BH2 induced inflammation response if 
a further increase in the BH2/BH4 ratio to 1:2.5. 
 
Hematoxylin and Eosin Staining 
 After the experiment, the loop of the ileal mesentery that was superfused with test 
solutions was removed and quickly placed in a 4% paraformaldehyde solution in PBS for 
future histological analysis of leukocyte-endothelial interactions via hematoxylin/eosin 
staining. At a later time, three representative sections of the ileal mesenteric tissue were 
selected from the Krebs’ control, 50 µM L-NAME, 100 µM BH2, 200 µM BH2, 250 µM 
BH4, 100 µM BH2/100 µM BH4, and 100 µM BH2/250 µM BH4 groups for histological 
analysis. The three samples for each group were chosen based on how close their 
leukocyte-endothelial interaction intravital microscopy data was to the mean value of the 
group. Each tissue sample was embedded in paraffin wax, cut into 4.5 µM serial sections, 
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and placed onto 25 x 75 x 1.0 mm Colorfrost
® 
microscope slides. These sections were 
later deparaffinized and rehydrated, stained with hematoxylin and eosin, and observed 
using light microscopy. Leukocyte adherence and transmigration into the tissue were 
counted in areas containing venules and arterioles in the serosa and mesentery. These 
numbers were expressed as adhered and transmigrated leukocytes/mm
2
 [7, 11].  
 
Statistical Analysis 
 All data will be represented as means ± SEM and analyzed by ANOVA using post 
hoc analysis with the Fisher’s PLSD test to detect differences among experimental groups 
within each aim.  Probability values are considered to be statistically significant when 
P<0.05.  
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Results 
 The initial MABP recordings were not significantly different among the seven 
experiment groups. Throughout the entire observation time, the MABP stayed within a 
normal range with mean values of 112 ± 5 mmHg at baseline and 108 ± 3 mmHg at 2 
hours. Blood flow within the selected venules was not directly measured, however 
throughout the experiment there were no apparent observable changes.  
 
 Leukocyte-Endothelial Interactions via Intravital Microscopy 
Rolling 
 Among the seven experimental groups, leukocyte rolling showed no significant 
difference at baseline (Fig. 6). Krebs’ buffer was maintained around 14±2 cells/minute 
during the entire observation period; consequently leukocyte rolling did not significantly 
change. By contrast, 50 µM L-NAME generated a significant increase in rolling 
beginning at the 60 minute interval and continuing throughout the rest of the observation 
period.  At the 2 hour time point, leukocyte rolling was significantly increased to 47±4 
cells/minute (n=6, P<0.05) compared to the Krebs’ buffer control. BH2 (100 µM) 
generated a significant increase in rolling throughout with entire 2 hour time period that 
finally increased to 51±3 cells/minute (n=6, P<0.01) at the last time interval. Similarly, 
when 200 µM BH2 was administered, rolling increased throughout all time periods with 
the mean being 59±10 cells/minute (results not shown in graph) at the 2 hour time period 
and was not different from 100 µM BH2. Thereafter, the 100 µM of BH2 was used to 
induce leukocyte-endothelial interactions in subsequent groups. 
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In order to determine the dose-dependent response in the BH2/BH4 ratio in 
leukocyte-endothelial interactions, both 100 µM BH2/100 µM BH4 and 100 µM/250 µM 
BH4 were used. In regards to the 1:1 ratio of BH2/BH4, leukocyte rolling significantly 
decreased in comparison to 100 µM BH2 at 30 minutes with 17±1 cells/minute to 60 
minutes with 16±2 cells/minute (n=6, P<0.05), but significantly increased rolling at later 
time points compared to Krebs’ buffer ending with 43±9 cells/minute (n=6, P<0.05) at 
the 120 minute interval. By contrast, decreasing the BH2 to BH4 ratio from 1:1 (i.e. 100 
µM BH2/100 µM BH4 ) to 1:2.5 (i.e. 100 µM BH2/250 µM BH4 ), significantly decreased 
BH2-induced rolling throughout the entire 2 hour observation period ending with 26±4 
cells/minute (n=6, P<0.01) at 120 minutes, which was not different from Krebs’ buffer. 
In regard to 250 µM of BH4, it was not significantly different from Krebs’ buffer 
throughout the entire observation period. However, it did show a modest decrease in 
leukocyte rolling at the 30, 60, 90  and 120 minute time periods with 13±1 cells/minute, 
9±1 cells/minute, 8±1 cells/minute, and 14±1 cells/minute respectively, in comparison to 
baseline with 22±1 cells/minute. Figure 6 illustrates leukocyte rolling among the given 
experimental groups. 
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Figure 6:  Leukocyte rolling among different experiment groups. L-NAME and 100 
µM BH2 significantly increased leukocyte rolling (*P<0.05, **P<0.01 
from Krebs’).  By contrast, BH2/BH4 dose-dependently decreased 
leukocyte rolling (#P<0.05, ##P<0.01 from 100 µM BH2). 
 
 
Adherence  
At baseline, there was no statistical significance among any of the experimental 
groups (Fig. 7). Krebs’ buffer maintained similar cell adhesion throughout the entire time 
period, with a slight increase towards the later time intervals, from baseline with 3±1 
cells/minute versus the 90 minutes with 5±0 cells/minute and 120 minutes with 6±1 
cells/minute. However, both L-NAME and 100 µM BH2 increased leukocyte adherence 
from baseline at all time points and became statistically significant at 90 and 120 minute 
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time periods with 10±2 cells/minute (n=6, P<0.01) and 17±2 cells/minute, respectively 
(n=6, P<0.01) for L-NAME and 9±1 cells/minute (n=6, P<0.05) and 11±1 cells/minute, 
respectively (n=6, P<0.05) for 100 µM BH2, both in comparison to Krebs’ buffer.  
For the 1:1 ratio of BH2/BH4 leukocyte adherence was similar to Krebs’ at 
baseline with 5±1 cells/minute and did not increase during the first 60 minutes.  
However, leukocyte adherence increased to 7±1 cells/minute and 9±2 cells/minute at 90 
and 120 minutes, respectively. The adherence data was not significantly different from 
BH2-induced leukocyte adherence at these time points. By contrast, decreasing the BH2 to 
BH4 ratio from 1:1 (i.e. 100 µM BH2/100 µM BH4 ) to 1:2.5 (i.e. 100 µM BH2/250 µM 
BH4 ), significantly decreased BH2-induced adherence at the 120 minute time period 
ending with 4±1 cells/minute (n=6, P<0.01), and was not different from Krebs’ buffer 
throughout the 2 hour time period. Regarding 250 µM of BH4, it was not significantly 
different from Krebs’ buffer in leukocyte adherence throughout the entire observation 
period. The differences in leukocyte adhesion among the different experimental groups 
are illustrated in Figure 7.  
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Figure 7:  Leukocyte adherence among different experiment groups. L-NAME and 
100 µM BH2 significantly increased leukocyte adherence (*P<0.05, 
**P<0.01 from Krebs’). By contrast, BH2/BH4 dose-dependently 
decreased leukocyte adherence (#P<0.05, ##P<0.01 from 100 µM BH2). 
 
 
Transmigration 
 Leukocyte transmigration was similar to rolling and adherence in that there were 
no significant changes at baseline among the experimental groups (Fig. 8). Over the 120 
minute observation period, Krebs’ buffer did not show any significant changes in 
leukocyte transmigration. In comparison to Krebs’ buffer, both L-NAME and 100 µM 
BH2 significantly increased throughout all time periods with L-NAME having 3±0 
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cells/minute (n=6, P<0.01) at 30 minutes and 10±1 cells/minute (n=6, P<0.01) at 120 
minutes, and 100 µM BH2 having 3±0 cells/minute (n=6, P<0.05) at 30 minutes and 7±0 
cells/minute (n=6, P<0.01) at 120 minutes.  
 When 100 µM BH2/100 µM BH4 was superfused at 30 minutes, there was a 
significant decrease in leukocyte transmigration with 2±0 cells/minute (n=6, P<0.01) in 
comparison to 100 µM BH2. This 1:1 combination lost its’ significant in comparison to 
BH2-induced leukocyte transmigration at all of the later time points although it was not 
different from Krebs’ buffer at any time point during the 2 hour observation period. In 
contrast, the 1:2.5 BH2/BH4 ratio significantly decreased BH2-induced leukocyte 
transmigration at all time points within the 2 hour observation period beginning with 2±0 
cells/minute (n=6, P<0.05) at 30 minutes and finishing up with 2±0 cells/minute (n=6, 
P<0.01) at 120 minutes, in comparison to 100 µM BH2 and was not different from the 
Krebs’ control. In regard to 250 µM of BH4, it was not significantly different from Krebs’ 
buffer in leukocyte transmigration throughout the entire observation period. Leukocyte 
transmigration is illustrated among the different experimental groups in Figure 8. 
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Figure 8:  Leukocyte transmigration among different experiment groups. L-NAME 
and 100 µM BH2 significantly increased leukocyte transmigration 
(*P<0.05, **P<0.01 from Krebs’). By contrast, decreasing the BH2/BH4 
ratio dose-dependently decreased BH2-induced leukocyte transmigration 
during all time periods. (#P<0.05, ##P<0.01 from 100 µM BH2). 
 
 
Leukocyte Adherence and Transmigration via Hematoxylin and Eosin (H&E) Staining 
 Hematoxylin and eosin were used to stain the nucleus and cytoplasm, 
respectively, in rat mesenteric tissue which was superfused by the test solutions 
throughout the experimental observation phase to further quantify leukocyte vascular 
adherence and transmigration. Neutrophils composed the majority of the adhered and 
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transmigrated leukocytes as seen under the light microscope, although a small percentage 
were found to be monocytes. Figures 9, 10, and 11 show representative H&E staining in 
the Krebs’ control, 50 µM L-NAME, 100 µM BH2, 200 µM BH2, 250 µM BH4, 100 µM 
BH2/100 µM BH4, and 100 µM BH2/250 µM BH4 groups. 
 Similar to leukocyte-endothelial interactions observed by intravital microscopy, 
there was low leukocyte adherence with 51 cells/mm
2
 and transmigration with 52 
cells/mm
2
 in the Krebs’ control group (Figure 12). By contrast, the 50 µM L-NAME 
group exhibited a five-fold increase in leukocyte adherence of 244 cells/mm
2
 (P<0.01) 
and transmigration of 286 cells/mm
2
 (P<0.01) compared to the Krebs’ buffer control. 
Results for both the 100 µM BH2 and 200 µM BH2 were similar to L-NAME with the 
adhered leukocytes containing 271 cells/mm
2 
(P<0.01) and 261 cells/mm
2
 (P<0.01), 
respectively, and the transmigrated containing 237 cells/mm
2 
(P<0.01) and 256 cells/mm
2
 
(P<0.01), respectively.  
  For the 100 µM BH2/100 µM BH4 ratio, leukocyte adherence was similar to BH2-
induced adherence with 203 cells/mm
2 
(P<0.01) and transmigration with 177.8 cells/mm
2 
(P<0.01) compared to Krebs’ buffer which is consistent with the intravital microscopy 
data at the 2 hour time period. Although similar to BH2, there was a modest, yet 
significant decrease in leukocyte adherence and transmigration compared to BH2. By 
contrast, decreasing the BH2/BH4 ratio (i.e. 100 µM BH2/250 µM BH4) resulted in 
significantly lower leukocyte adherence and transmigration with 28 cells/mm
2 
(P<0.01) 
and 21 cells/mm
2 
(P<0.01), respectively compared to BH2 which is also consistent with 
intravital microscopy data. The 250 µM BH4 group showed a decreased leukocyte 
adherence and transmigration with 29 cells/mm
2 
that adhered and 22 cells/mm
2
 that 
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transmigrated, but it was not statistically different from the Krebs’ control which 
corresponds with intravital microscopy data. The summary data among the experimental 
groups is illustrated in Figure 12.  
 
 
 
 
Figure 9:  Representative pictures of leukocytes by H&E staining of mesenteric 
tissues from Krebs’ control (9A & 9B), 50 M L-NAME (9C & 9D), and 
100 M BH2 (9E & 9F). 9A, 9C, & 9E are at 10x while 9B, 9D, and 9F 
are at 40x. Compared to Krebs’ control, the L-NAME and 100 M BH2 
treated groups exhibited a marked increase in adhered and transmigrated 
leukocytes.  Arrow head indicates leukocyte adherence and full arrow 
indicates leukocyte transmigration. Scale bar: 50 µm. 
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Figure 10: Representative pictures of leukocytes by H&E staining of mesenteric 
tissues from 200 M BH2 (10A & 10B) and 250 M BH4 (10C & 10D). 
10A & 10C are at 10x while 10B & 10D are at 40x. Compared to both 
concentrations of BH2 (100 M BH2 in figure 9E & 9F), the BH4 treated 
group exhibited a marked decrease in adhered and transmigrated 
leukocytes. Arrow head indicates leukocyte adherence and full arrow 
indicates leukocyte transmigration. Scale bar: 50 µm.  
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Figure 11: Representative pictures of leukocytes by H&E staining of mesenteric 
tissues  from 100 M BH2/100 M BH4 (11A & 11B), and 100 M 
BH2/250 M BH4 (11C & 11D). 11A & 11C are at 10x while 11C & 11D 
are at 40x. Compared to 100 M BH2, the 100 M BH2/100 M BH4 
treated group exhibited a decrease in adhered and transmigrated 
leukocytes, and the 100 M BH2/250 M BH4 showed a further decrease 
in induced leukocyte-endothelial interactions. Arrow head indicates 
leukocyte adherence and full arrow indicates leukocyte transmigration. 
Scale bar: 50 µm. 
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Figure 12: Leukocyte adherence and transmigration by H&E staining of mesenteric 
tissues from Krebs’ control, 50 µM L-NAME, 100 µM BH2, 200 µM BH2, 
250 µM BH4, 100 µM BH2/100 µM BH4, and 100 µM BH2/250 µM BH4. 
Compared to Krebs control, the L-NAME and 100/200 µM BH2 treated 
groups exhibited a significant increase in adhered and transmigrated 
leukocytes (**P<0.01 from Krebs’). By contrast, 100 µM BH2/100 µM 
BH4 (††P<0.01 from 100 µM BH2, Krebs’, and 100 µM BH2/250 µM 
BH4) and 100 µM BH2/250 µM BH4 (##P<0.01 from 100 µM BH2) 
significantly decreased leukocyte adherence and transmigration compared 
to 100 µM BH2, whereas the 100 µM BH2/100 µM BH4 also significantly 
increased leukocyte adherence and transmigration in comparison to Krebs’ 
buffer and 100 µM BH2/250 µM BH4.  
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Discussion 
Summary of Major Findings 
 The major findings in this study were as follows: 1.) 50 µM L-NAME, 100 µM 
BH2, and 200 µM BH2 similarly and significantly increased leukocyte-endothelial 
interactions compared to Krebs’ buffer control group.  2.) The administration of the 
BH2/BH4 dose-dependently (i.e. 1: 2.5 ratio compared to 1:1 ratio) attenuated the 
leukocyte-endothelial interactions in comparison to the 100 µM BH2. 3.) H&E staining of 
the experimentally superfused mesenteric tissue from 50 µM L-NAME, 100 µM BH2, 
and 200 µM BH2 groups showed a significant increase in leukocyte vascular adherence 
and transmigration compared to the Krebs’ buffer control group. This result confirmed 
the inflammatory effects of the BH2 and L-NAME observed via intravital microscopy. 4.) 
Furthermore, H&E staining of the experimentally superfused mesenteric tissue from 250 
µM BH4, 100 µM BH2/100 µM BH4, and 100 µM BH2/250 µM BH4 showed a significant 
decrease in leukocyte vascular adherence and transmigration compared to the 100 µM 
BH2. Increasing the BH4 to BH2 ratio correlated with better attenuation of leukocyte-
endothelial interactions suggesting that promoting coupled eNOS activity contributed to 
the anti-inflammatory effects of BH4. Therefore, this study supports the anti-
inflammatory effects of BH4 when the vascular endothelium becomes dysfunctional by 
promoting eNOS coupled status.  
 
 Effects of L-NAME on Leukocyte-Endothelial Interactions 
 Superfusion of Krebs’ buffer alone for 2 hours did not significantly increase 
leukocyte-endothelial interactions.  The data suggests that the animal preparation and the 
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superfusion of a physiological solution (i.e. Krebs’ buffer) for 2 hours did not 
significantly induce an inflammatory response.  By contrast, L-NAME significantly 
increased leukocyte rolling, adherence, and transmigration during 2 hours of superfusion 
compared to the Krebs’ control group. This result is consistent with previous studies that 
found 50 µM L-NAME to consistently increase the number of rolling, adhered, and 
transmigrated leukocytes [11, 41].  A study conducted by Kubes et. al. also discovered 
that L-NAME-induced leukocyte vascular adherence can be completely overturned by 
increasing the concentration of exogenous L-arginine by five times. [42]. This suggests 
the increase in L-NAME-induced leukocyte-endothelial interactions transpires because L-
NAME competes with L-arginine for the active site in eNOS resulting in decreased NO 
release. The decrease in NO release in turn leads to endothelial dysfunction and 
inflammation [11, 41]. Thus, this project further supports that L-NAME is an effective 
agent that synthetically reproduces endothelial dysfunction and causes leukocyte-
endothelial interactions in rat mesenteric tissue.  
 
BH2 Effects Compared to L-NAME on Leukocyte-Endothelial Interactions 
 BH2 and L-NAME both showed an increase from baseline in leukocyte-
endothelial interactions throughout the entire observation period. Because L-NAME is a 
nonselective NOS inhibitor, it competes with L-arginine to inhibit NO production, 
causing SO to be released instead of NO [6]. As a result, L-NAME caused an increase in 
leukocyte rolling, adherence, and transmigration during the intravital microscopy 
experiments, which is additionally well-noted in previous literature [11, 41]. By contrast, 
BH4 or BH2 serve as cofactors to determine eNOS production of NO or SO, respectively. 
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Normally, BH4 binds to the oxygenase domain of eNOS and facilities the eNOS coupled 
status and generates NO. Whereas when BH4 becomes oxidized to BH2, the electron 
transfer becomes uncoupled to the L-arginine oxidation. Consequently, the ferrous-
dioxygen complex dissociates and SO is generated from the oxygenase domain from 
molecular oxygen [8]. Similar to L-NAME, BH2 administration resulted in an increase in 
leukocyte-endothelial interactions at all time points throughout the 2 hour observation 
period. BH2 was superfused to induce inflammation in this study and change the 
intracellular BH2/BH4 ratio causing eNOS uncoupling which simulates the eNOS changes 
under some pathophysiological conditions such as I/R or hyperglycemia. Thus, L-NAME 
cannot change the eNOS coupled or uncoupled status compared to modulating the ratio 
of the BH4 to BH2. It is known that reduced serum BH4 levels are associated with 
coronary artery disease and hypertension [36]. This study suggests that BH2-induced 
inflammation model is more suitable to test the effects of eNOS regulation under various 
pathophysiological conditions.  
 
Effects of BH2/BH4 on Leukocyte-Endothelial Interactions 
At baseline, there was no significant difference among any of the experimental 
groups in this study for rolling, adherence, transmigration, or mean arteriolar blood 
pressure (MABP).  This finding denotes that the initial conditions after preparation of the 
rat were similar among the various experimental groups. In contrast to the L-NAME- and 
100 µM BH2-induced increases in leukocyte-endothelial interactions, decreasing the 
BH2/BH4 ratio dose-dependently attenuated leukocyte rolling, adherence, and 
transmigration in rat postcapillary venules. The 1:1 ratio (i.e. 100 µM BH2/100 µM BH4) 
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significantly reduced leukocyte rolling, adherence, and transmigration only within the 
first 60 minutes of superfusion, whereas the 1:2.5 ratio decreased leukocyte rolling, 
adherence, and transmigration throughout the entire 2 hour period. For the 1:1 ratio, this 
may be due to increased oxidation of BH4 later in the observation period which would in 
turn increase the BH2 to BH4 ratio and promote rather than attenuate leukocyte-
endothelial interactions. Determination of the BH2 to BH4 ratio by high performance 
liquid chromatography (HPLC) in tissue obtained at the end of the experiment will 
address this issue in future studies.  
Differing cellular adhesion molecule regulation may play a role in the dose-
dependent effects of the BH2/BH4 ratio on leukocyte-endothelial interactions. In the case 
of this study, the 250 µM concentration of BH4 in combination with 100 µM BH2 
attenuated BH2-induced leukocyte-endothelial interactions and was more effective than 
100 µM BH4.  It is also probable that the more effective dose-dependent response of BH4 
on leukocyte transmigration is due to the cumulative attenuation of leukocyte rolling and 
adherence before diapedesis occurs. 
The 100 µM BH2 concentration was chosen to use in the BH2/BH4 ratio instead of 
the 200 µM BH2 concentration because results from both concentrations were almost 
identical. Moreover, in light of the current data, one would have to use a higher dose of 
BH4 (i.e. 500 µM) to overcome the BH2 effect. Previous studies also used this 
concentration (i.e. 100 µM BH2) effectively to increase H2O2 release in femoral I/R and 
to decrease NO release [7]. Additionally, the 250 µM BH4 concentration was chosen to 
use in the BH2/BH4 ratio with 100 µM BH2 because significance was lost after 60 
minutes for rolling and adhered leukocytes while superfusing the 100 µM BH4 
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concentration [7]. Once the higher concentration of BH4 was used, significance returned 
at all of the time points throughout the 2 hour period in comparison to the 100 µM BH2. 
Moreover, the 250 µM of BH4 correlates with previous femoral I/R in vivo studies that 
showed decreased H2O2 and increased NO release [7].  
Although research on the effects of the BH2/BH4 ratio has been limited, previous 
studies have noted that this ratio may be the determining factor in causing endothelial 
dysfunction. Vasquez-Vivar et. al. showed that increasing the ratio between BH2 and BH4 
tightly regulates SO formation from eNOS [6]. They also note that the augmentation of 
BH4 should increase NO formation; while the high turnover of BH4 leading to an increase 
in oxidized BH4 (i.e. BH2) causes SO production by eNOS [43]. Therefore, the results 
from this in vivo study support the concept that increasing the BH2/BH4 ratio promotes 
endothelial dysfunction and thereby increases leukocyte-endothelial interactions observed 
via intravital microscopy. These results also indirectly support the concept of previous in 
vitro studies suggesting that increasing the BH2/BH4 ratio results in increased vascular 
oxidative stress leading to enhanced inflammation responses [7].  
Clinical studies have found a positive correlation between the BH4/BH2 ratio and 
flow mediated vasodilatation (FMD). FMD is induced by reactive hyperemia (via the 
release of a blood pressure cuff) and is considered a method to assess the relationship 
between coronary risk factors and endothelial dysfunction. This study also found that 
patients with multiple coronary risk factors had a decreased serum BH4/BH2 ratio and 
those that underwent treatment with statins had improved FMD with an increased 
BH4/BH2 ratio. Furthermore, this clinical research shows plasma pteridine levels (i.e. 
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BH4/BH2 ratio) can be used as a biomarker to evaluate endothelial dysfunction in the 
absence of evident systemic inflammation [36].  
H&E staining of the mesenteric tissue superfused with 100 µM BH2 and 200 µM 
BH2 showed a significant increase in leukocyte vascular adherence and transmigration in 
comparison the Krebs’s buffer. By contrast, increasing the BH4/BH2 from 1:1 to 2.5:1 
exhibited a dose-dependent and marked decrease in leukocyte adherence and 
transmigration in comparison to BH2 alone. This decrease in the number of leukocytes in 
the BH2/BH4 ratio test solution groups confirms the dose-dependent and anti-
inflammatory effects of BH4 observed during intravital microscopy.  
 
 
Mechanism of Action Related to Anti-Inflammatory Effects of Reducing the BH2/BH4 
Ratio 
 The mechanism of increasing SO production to induce leukocyte rolling and 
adherence due to oxidative stress, and reversing those leukocyte-endothelial interactions 
via superoxide dismutase has been well established in the scientific community [42]. 
However, this is the first study to show that eNOS uncoupling can induce inflammation 
in vivo by intravital microscopy in the rat mesenteric circulation. There are numerous 
mechanisms involved in the effect of eNOS uncoupling on NO bioavailability in vascular 
conditions. The uncoupling of eNOS may be an important mechanism mediating 
inflammation-induced vascular injury. One of the most important roles is played by BH4 
where it acts to regulate NO and SO production by eNOS [44]. NO is produced from 
coupled eNOS as a dimer under normal conditions where BH4 acts an essential cofactor 
stabilizing the eNOS dimer and facilitates the electron transfer. BH4 promotes eNOS 
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dimerization, protein stability, and NO synthesis making it a modulator of eNOS function 
[45].  
Heitzer et. al. demonstrated the that positive effects of acute BH4 administration 
in chronic smokers was most likely by way of a direct effect on eNOS coupling versus 
merely an antioxidant effect. This was noted because a control infusion of 
tetrahydroneopterin (NH4), another reduced pteridine, had no effect on endothelial 
function despite having a comparable capacity to scavenge SO anions like BH4 in vitro 
[44, 46].  As a result, BH4 can be directly linked to these positive findings improving 
vasodilation in chronic smokers. Because BH4 can be oxidized into BH2 when oxidative 
stress exists, the BH2/BH4 ratio plays an essential role in mediating inflammation-induced 
vascular injury. Our study is unique in that altering the cofactor status can be just as 
effective at studying inflammation and may be more clinically relevant than synthetically 
inhibiting L-arginine. 
 Additionally, several studies have shown that administration of ascorbate (vitamin 
C) may be an important aspect in maintaining BH4 levels in the presence of oxidative 
stress. It has been shown to ameliorate endothelial dysfunction in patients with diabetes, 
hypercholesterolemia, overt coronary artery disease, as well as those who smoke [44]. 
Supplementation with vitamin C increased the BH4/BH2 ratio and NO bioavailability in 
apolipoprotein E knock-out mice in a study conducted by d’Uscio et. al [47]. They found 
that there is a dose-dependent effect of ascorbate on BH4 levels and NO synthesis in 
cultured endothelial cells, although this mechanism is not fully understood [44, 47]. 
Current research indicates that maintaining BH4 levels in endothelium is essential in 
regulating the NO balance and SO synthesis by eNOS [44].  
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  The pro-inflammatory or anti-inflammatory effects of the BH2/BH4 ratio have 
been proposed in numerous review articles and research studies. There have not been 
many in vivo experiments conducted in order to further prove this finding; yet future 
studies aim to confirm these results. Specifically, measurement of BH4/BH2 in tissue 
samples from clinical and basic research may confirm the significance of uncoupled 
eNOS as a major source of oxidative stress in pathophysiological conditions such as 
diabetes, atherosclerosis, hypertension, and I/R injury. This current project is one of the 
few that established an innovative animal model which functions by altering the BH2/BH4 
ratio thus investigating the role of eNOS uncoupling in vascular conditions. An early 
characteristic of all pathophysiological vascular diseases and risk factors associated with 
them is endothelial dysfunction, resulting in abnormal homoeostatic pathways which will 
exacerbate disease processes such as inflammation, thrombosis and oxidative stress [8]. 
The BH2/BH4 ratio is one area that can be targeted in preventing and improving 
inflammation-induced vascular injury.  
 
Clinical Relevance 
 Data suggest that eNOS uncoupling may be an important mechanism mediating 
inflammation-induced vascular injury. Decreased leukocyte-endothelial interactions by 
BH4 correlates with previous studies in our lab which include improved post-reperfused 
cardiac function (ex vivo), reduced H2O2 release and increased NO release in femoral I/R 
(in vivo), increased NO release from aortic segments (in vitro) [7]. This data in 
conjunction with the present study suggests that adding BH4 to pathological conditions 
may lessen the effects of vascular injury associated with I/R, hypertension, diabetes, 
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atherosclerosis, and hyperglycemia. Additionally, this study established an innovative 
BH2-induced leukocyte-endothelial interactions in an animal model by modulating the 
ratio between BH2 /BH4, exploring the role of eNOS uncoupling under 
pathophysiological conditions, as well as assisting in discovering potential therapeutic 
strategies. 
 
Limitations/Future Studies 
Three main limitations were present in this study. First, our lab was unable to 
acquire an optical Doppler velocimeter to observe erythrocyte velocity in order to 
determine the venular shear rates.  Nevertheless, we were able to monitor the blood flow 
throughout the experiment using intravital microscopy and no significant changes were 
detected among any of the experimental groups. Moreover, there were no significant 
differences in MABP among all groups at baseline, suggesting that blood flow would not 
be significantly different in any group.  In addition, it has been found that superfusion of 
some of the treatment groups (i.e. Krebs’, L-NAME) in this study do not cause 
significant effects on venular shear rates [48]. Therefore, given these conditions, shear 
rate most likely does not play a major role in increasing leukocyte-endothelial 
interactions.   
Secondly, this research project was one of the first of its kind to increase the ratio 
of BH2/BH4 to simulate vascular endothelial dysfunction in vivo making it a pilot study. 
We chemically induced endothelial dysfunction by administering L-NAME and BH2. To 
relate a more pathological condition to the BH2/BH4 ratio, future studies are aimed at 
inducing superior mesenteric artery ischemia/reperfusion to induce endothelial 
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dysfunction and subsequent endothelial-leukocyte interactions and to see if this effect can 
be attenuated or exacerbated by BH4 or BH2 respectively. These future experiments are 
planned in order to compare the results from these endothelial dysfunction-causing agents 
to those found under experimental I/R conditions regarding the BH2/BH4 ratio. Thirdly, 
although specific concentrations of the test solutions were superfused over the mesentery, 
there is no real way to know the absolute concentrations of BH4/BH2 inside the 
mesenteric venule circulation, versus the amount administered. Therefore, future studies 
are planned to detect BH4/BH2 levels using HPLC in tissue obtained at the end of 
intravital microscopy. One would speculate that the effects of the higher dose of BH4 (i.e. 
250 µM) would at the very least to show a 1:1 ratio or better. Conversely, the lower dose 
of BH4 (i.e. 100 µM) most likely would detect an increased BH2 to BH4 ratio rather than 
the 1:1 ratio that was used at the beginning of the experiment.  
Future challenges include identifying new strategies that target BH4 
supplementation, synthesis, and/or stabilization with sufficient potency and specificity in 
long term clinical studies. In the near future, our lab has plans to use BH2 combined with 
an eNOS activator (i.e. protein kinase C epsilon activator) to exacerbate BH2-induced 
leukocyte-endothelial interactions. Whereas, increasing the BH4/BH2 ratio combined with 
the eNOS activator should attenuate the BH2-induced effects. Additionally, we plan to 
use an eNOS inhibitor (i.e. protein kinase C epsilon inhibitor, or PKCε-) that theoretically 
should attenuate the BH2-induced leukocyte-endothelial interactions in contrast to L-
NAME since it will not compete with L-arginine to induce its’ effects. However, the 
effects of PKCε- may not be ameliorated in the case of BH4. 
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Summary and Significance of Major Findings 
 In summary, our data demonstrates that administration of BH4 dose-dependently 
attenuated BH2-induced leukocyte-endothelial interactions. The mechanism of this anti-
inflammatory action is associated with reduced oxidative stress and the restoration of 
vascular endothelial function. Our data provides indirect evidence to support that the 
BH2/BH4 ratio may be a potential strategy to attenuate endothelial-dysfunction induced 
inflammatory responses in different diseases such as diabetes, I/R injury, atherosclerosis, 
and hypertension. 
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